

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	wo-9805792-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:04
L2	65	jockers.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:05
L3	438	couturier.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:05
L4	1089	uhlmann.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:05
L5	8	I2 and (ob-rgrp or ob or rgrp or leptin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:08
L6	2	I5 and antisense	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:08
L7	10	I3 and (ob-rgrp or ob or rgrp or leptin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:11
L8	2	I7 and antisense	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:09
L9	8	I4 and (ob-rgrp or ob or rgrp or leptin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:18
L10	89	ob-rgrp or ob adj rgrp	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10

L11	138	bailleul.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L12	2	L11 and L10	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L13	0	L12 and antisense	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L14	4	L11 and leptin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L15	2	L14 and antisense	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
L16	309786	(ob-rgrp or ob or rgrp or leptin)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:11
L17	62427	antisense sirna ribozyme	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:11
L18	3091	L17 and L16	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/09/01 11:12
L19	2156	inhibition gene expression and L18	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/09/01 11:12
L20	172	L19 and @py<"2002"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/09/01 11:14

L21	1160	l18 not ob	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/09/01 11:14
L22	44	l21 and l19 and @py<"2002"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:15
L23	86	ob-rgrp and (antisense or sirna)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:18
S1	7	"925302".ap.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 09:04
S3	89	ob-rgrp or ob adj rgrp	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/08/31 10:40
S4	138	bailleul.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/08/31 10:41
S5	2	S4 and S3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/01 11:10
S6	4	S4 and leptin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/08/31 11:13

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	27	AUG 11	Derwent World Patents Index(R) web-based training during August
NEWS	28	AUG 11	STN AnaVist workshops to be held in North America
NEWS	29	AUG 30	CA/CAPLUS - Increased access to 19th century research documents
NEWS	30	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:26:51 ON 01 SEP 2005

=> file medline biosis caplus embase
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 11:27:12 ON 01 SEP 2005

FILE 'BIOSIS' ENTERED AT 11:27:12 ON 01 SEP 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:27:12 ON 01 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:27:12 ON 01 SEP 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

=> e couturier/au

E1	2	COUTURIE S/AU
E2	1	COUTURIE STEPHEN HENRY/AU
E3	6 -->	COUTURIER/AU
E4	120	COUTURIER A/AU
E5	1	COUTURIER A J/AU
E6	3	COUTURIER ALAIN/AU
E7	1	COUTURIER ALAIN J/AU
E8	2	COUTURIER ALBERT/AU
E9	8	COUTURIER ALEXIA/AU
E10	22	COUTURIER ANDRE/AU
E11	5	COUTURIER ANDREA/AU
E12	19	COUTURIER ANNE/AU

=> e

E13	1	COUTURIER AUDREY/AU
E14	10	COUTURIER B/AU
E15	1	COUTURIER BERNARD/AU
E16	2	COUTURIER BERTRAND/AU
E17	6	COUTURIER BHAUD Y/AU
E18	131	COUTURIER C/AU
E19	4	COUTURIER C A/AU
E20	2	COUTURIER C P/AU
E21	3	COUTURIER C Y/AU
E22	1	COUTURIER C Y R/AU
E23	3	COUTURIER CATHERINE/AU
E24	3	COUTURIER CEDRIC/AU

=> e

E25	1	COUTURIER CELINE/AU
E26	4	COUTURIER CH/AU
E27	3	COUTURIER CHRISTIAN/AU
E28	6	COUTURIER CHRISTINE/AU
E29	5	COUTURIER CYR/AU
E30	16	COUTURIER CYRIL/AU
E31	563	COUTURIER D/AU
E32	1	COUTURIER D E/AU
E33	172	COUTURIER DANIEL/AU
E34	1	COUTURIER DANIEL C/AU
E35	1	COUTURIER DONALD I/AU

E36 182 COUTURIER E/AU

=> s e18 and e30

L1 0 "COUTURIER C"/AU AND "COUTURIER CYRIL"/AU

=> s e18,30

L2 0 E18,30

=> s e18;e30

L3 131 "COUTURIER C"/AU

E30 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s e18 or e30

L4 147 "COUTURIER C"/AU OR "COUTURIER CYRIL"/AU

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 93 DUP REM L4 (54 DUPLICATES REMOVED)

=> s l5 and leptin and antisense

L6 1 L5 AND LEPTIN AND ANTISENSE

=> dis ti so au kwic

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

TI **Antisense** oligonucleotides inhibiting expression of OB-RGRP
protein and method for identifying compounds modifying OB-RGRP protein-
leptin receptor interaction

SO Fr. Demande, 104 pp.

CODEN: FRXXBL

IN Jockers, Ralf; **Couturier, Cyril**; Uhlmann, Eugen

TI **Antisense** oligonucleotides inhibiting expression of OB-RGRP
protein and method for identifying compounds modifying OB-RGRP protein-
leptin receptor interaction

IN Jockers, Ralf; **Couturier, Cyril**; Uhlmann, Eugen

AB **Antisense** oligonucleotides inhibiting expression of the gene
encoding the OB-RGRP (Ob receptor gene-related protein) protein and their
uses for the prevention and/or treatment of pathologies related to
leptin. A method for identifying compds. modifying the
interaction between OB-RGRP and the **leptin** receptor is also
disclosed. This method comprises uses of OB-RGRP and **leptin**
receptor fusion proteins with proteins such as luciferase and YFP (a
mutant of GFP) and measurement of the transfer of energy between these
fusion proteins. Thus, in cells expressing OB-RGRP and treated with
OB-RGRP **antisense** oligonucleotide the basal and **leptin**
-stimulated signaling by **leptin** receptor was enhanced.
Interaction of **leptin** receptor and OB-RGRP was detected by
bioluminescence resonance energy transfer in cells coexpressing
leptin receptor-luciferase and OB-RGRP-YFP fusion proteins.

ST **antisense** oligonucleotide siRNA **leptin** receptor
related protein OB RGRP; drug screening fusion protein **leptin**
receptor luciferase OBRGRP YFP

IT **Antisense** oligonucleotides

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2'-O-methylnucleoside-containing; **antisense** oligonucleotides
inhibiting expression of OB-RGRP protein and method for identifying
compds. modifying OB-RGRP protein-**leptin** receptor
interaction)

IT Proteins

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)

(EYFP, fusion with **leptin** receptor or OB-RGRP;
antisense oligonucleotides inhibiting expression of OB-RGRP
protein and method for identifying compds. modifying OB-RGRP protein-
leptin receptor interaction)

IT Proteins
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
study); USES (Uses)
(OB-RGRP (**leptin** receptor gene-related protein), fusion with
fluorescent proteins; **antisense** oligonucleotides inhibiting
expression of OB-RGRP protein and method for identifying compds.
modifying OB-RGRP protein-**leptin** receptor interaction)

IT Proteins
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(Topaz, fusion with **leptin** receptor or OB-RGRP;
antisense oligonucleotides inhibiting expression of OB-RGRP
protein and method for identifying compds. modifying OB-RGRP protein-
leptin receptor interaction)

IT Drug screening
Human
(**antisense** oligonucleotides inhibiting expression of OB-RGRP
protein and method for identifying compds. modifying OB-RGRP protein-
leptin receptor interaction)

IT **Antisense** oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**antisense** oligonucleotides inhibiting expression of OB-RGRP
protein and method for identifying compds. modifying OB-RGRP protein-
leptin receptor interaction)

IT Resonance energy transfer
(bioluminescence; **antisense** oligonucleotides inhibiting
expression of OB-RGRP protein and method for identifying compds.
modifying OB-RGRP protein-**leptin** receptor interaction)

IT DNA sequences
(for human **leptin** receptor and OB-RGRP protein fused to
fluorescent protein YFP or luciferase)

IT **Leptin** receptors
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
study); USES (Uses)
(fusion with fluorescent proteins; **antisense** oligonucleotides
inhibiting expression of OB-RGRP protein and method for identifying
compds. modifying OB-RGRP protein-**leptin** receptor
interaction)

IT Proteins
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(green fluorescent, GFPS65T, fusion with **leptin** receptor or
OB-RGRP; **antisense** oligonucleotides inhibiting expression of
OB-RGRP protein and method for identifying compds. modifying OB-RGRP
protein-**leptin** receptor interaction)

IT Proteins
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(green fluorescent, fusion with **leptin** receptor or OB-RGRP;
antisense oligonucleotides inhibiting expression of OB-RGRP
protein and method for identifying compds. modifying OB-RGRP protein-
leptin receptor interaction)

IT Post-transcriptional processing
(interference; **antisense** oligonucleotides inhibiting
expression of OB-RGRP protein and method for identifying compds.
modifying OB-RGRP protein-**leptin** receptor interaction)

IT Protein sequences
(of human **leptin** receptor and OB-RGRP protein fused to
fluorescent protein YFP or luciferase)

IT **Antisense** oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphorothioate-linked; **antisense** oligonucleotides
inhibiting expression of OB-RGRP protein and method for identifying
compds. modifying OB-RGRP protein-**leptin** receptor

interaction)

IT Double stranded RNA
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (small interfering; **antisense** oligonucleotides inhibiting
 expression of OB-RGRP protein and method for identifying compds.
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT **Antisense** oligonucleotides
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (triethylene glycol-terminated; **antisense** oligonucleotides
 inhibiting expression of OB-RGRP protein and method for identifying
 compds. modifying OB-RGRP protein-**leptin** receptor
 interaction)

IT Proteins
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
 study); USES (Uses)
 (yellow fluorescent, fusion with **leptin** receptor or OB-RGRP;
antisense oligonucleotides inhibiting expression of OB-RGRP
 protein and method for identifying compds. modifying OB-RGRP protein-
leptin receptor interaction)

IT 736653-92-2
 RL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (OB-RGRP **antisense** oligonucleotide; **antisense**
 oligonucleotides inhibiting expression of OB-RGRP protein and method
 for identifying compds. modifying OB-RGRP protein-**leptin**
 receptor interaction)

IT 737464-32-3
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (OB-RGRP **antisense** oligonucleotide; **antisense**
 oligonucleotides inhibiting expression of OB-RGRP protein and method
 for identifying compds. modifying OB-RGRP protein-**leptin**
 receptor interaction)

IT 737464-35-6 737464-37-8 737464-39-0 737464-41-4 737464-44-7
 737464-46-9
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
 study); USES (Uses)
 (amino acid sequence; **antisense** oligonucleotides inhibiting
 expression of OB-RGRP protein and method for identifying compds.
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-33-4 737464-42-5, Protein MY47 (human)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; **antisense** oligonucleotides inhibiting
 expression of OB-RGRP protein and method for identifying compds.
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT 9014-00-0D, Luciferase, fusion with **leptin** receptor or OB-RGRP
 RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical
 study); USES (Uses)
 (**antisense** oligonucleotides inhibiting expression of OB-RGRP
 protein and method for identifying compds. modifying OB-RGRP protein-
leptin receptor interaction)

IT 737464-31-2
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (nucleotide sequence; **antisense** oligonucleotides inhibiting
 expression of OB-RGRP protein and method for identifying compds.
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-34-5 737464-36-7 737464-38-9 737464-40-3 737464-43-6
 737464-45-8 737464-47-0
 RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological
 study); USES (Uses)
 (nucleotide sequence; **antisense** oligonucleotides inhibiting
 expression of OB-RGRP protein and method for identifying compds.
 modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-74-3, 3: PN: FR2850971 SEQID: 3 unclaimed DNA 737464-75-4, 9: PN: FR2850971 SEQID: 9 unclaimed DNA 737464-77-6
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; **antisense** oligonucleotides inhibiting expression of OB-RGRP protein and method for identifying compds. modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-76-5
 RL: PRP (Properties)
 (unclaimed protein sequence; **antisense** oligonucleotides inhibiting expression of OB-RGRP protein and method for identifying compds. modifying OB-RGRP protein-**leptin** receptor interaction)

IT 737464-78-7 737464-79-8 737464-80-1 737464-81-2 737464-82-3
 737464-83-4 737464-84-5 737464-85-6 737464-86-7 737464-87-8
 737464-88-9 737464-89-0 737464-90-3 737464-91-4 737464-92-5
 737464-93-6
 RL: PRP (Properties)
 (unclaimed sequence; **antisense** oligonucleotides inhibiting expression of OB-RGRP protein and method for identifying compds. modifying OB-RGRP protein-**leptin** receptor interaction)

=> dis ibib

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:650986 CAPLUS
 DOCUMENT NUMBER: 141:185931
 TITLE: **Antisense** oligonucleotides inhibiting expression of OB-RGRP protein and method for identifying compounds modifying OB-RGRP protein-**leptin** receptor interaction
 INVENTOR(S): Jockers, Ralf; **Couturier, Cyril**; Uhlmann, Eugen
 PATENT ASSIGNEE(S): Aventis Pharma S. A., Fr.; Institut National de la Sante et de la Recherche Medicale INSERM
 SOURCE: Fr. Demande, 104 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
FR 2850971	A1	20040813	FR 2003-1543	20030210
WO 2004072293	A2	20040826	WO 2004-FR294	20040209
WO 2004072293	A3	20040923		
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2005009042 A1 20050113 US 2004-774721 20040209
 PRIORITY APPLN. INFO.: FR 2003-1543 A 20030210
 US 2003-461005P P 20030407
 REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```

=> s ob-rgrp
L7          45 OB-RGRP

=> s antisense or sirna
L8          114357 ANTISENSE OR SIRNA

=> s 17 and 18
L9          4 L7 AND L8

=> dup rem
ENTER L# LIST OR (END):19
PROCESSING COMPLETED FOR L9
L10         4 DUP REM L9 (0 DUPLICATES REMOVED)

=> dis ti so au l10 1-4

L10 ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
TI  Antisense oligonucleotides inhibiting expression of OB
    -RGRP protein and method for identifying compounds modifying
    OB-RGRP protein-leptin receptor interaction
SO  Fr. Demande, 104 pp.
    CODEN: FRXXBL
IN  Jockers, Ralf; Couturier, Cyril; Uhlmann, Eugen

L10 ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
TI  Genes that are differentially expressed during erythropoiesis and their
    diagnostic and therapeutic uses
SO  PCT Int. Appl., 285 pp.
    CODEN: PIXXD2
IN  Brissette, William H.; Neote, Kuldeep S.; Zagouras, Panayiotis; Zenke,
    Martin; Lemke, Britt; Hacker, Christine

L10 ANSWER 3 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
TI  Gene expression profiles in bone and cartilage formation and their use in
    diagnosis and treatment of disease
SO  PCT Int. Appl., 197 pp.
    CODEN: PIXXD2
IN  Clancy, Brian; Pittman, Debra M.

L10 ANSWER 4 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
TI  Nucleic acid compositions, kits, and methods for identification,
    assessment, prevention, and therapy of human breast cancer
SO  PCT Int. Appl., 2674 pp.
    CODEN: PIXXD2
IN  Lillie, James; Palermo, Adam; Wang, Youzhen; Steinmann, Kathleen; Elias,
    Josh

=> dis ibib l10 2-4

L10 ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:409169  CAPLUS
DOCUMENT NUMBER: 138:380506
TITLE: Genes that are differentially expressed during
    erythropoiesis and their diagnostic and therapeutic
    uses
INVENTOR(S): Brissette, William H.; Neote, Kuldeep S.; Zagouras,
    Panayiotis; Zenke, Martin; Lemke, Britt; Hacker,
    Christine
PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Max-Delbrueck-Centrum Fuer
    Molekulare Medizin
SOURCE: PCT Int. Appl., 285 pp.
    CODEN: PIXXD2

```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038130	A2	20030508	WO 2002-XA34888	20021031
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003038130	A2	20030508	WO 2002-US34888	20021031
WO 2003038130	A3	20040212		
WO 2003038130	C1	20040422		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
US 2001-335048P P 20011031
US 2001-335183P P 20011102
WO 2002-US34888 A 20021031

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:832556 CAPLUS
DOCUMENT NUMBER: 137:350862
TITLE: Gene expression profiles in bone and cartilage formation and their use in diagnosis and treatment of disease
INVENTOR(S): Clancy, Brian; Pittman, Debra M.
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085285	A2	20021031	WO 2002-US12149	20020418
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
US 2001-284786P P 20010418

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:116539 CAPLUS
 DOCUMENT NUMBER: 136:146231
 TITLE: Nucleic acid compositions, kits, and methods for
 identification, assessment, prevention, and therapy of
 human breast cancer
 INVENTOR(S): Lillie, James; Palermo, Adam; Wang, Youzhen;
 Steinmann, Kathleen; Elias, Josh
 PATENT ASSIGNEE(S): Millennium Predictive Medicine, Inc., USA
 SOURCE: PCT Int. Appl., 2674 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046697	A2	20010628	WO 2000-US35214	20001221
WO 2001046697	A3	20020110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
 US 1999-171406P P 19991221
 US 2000-176423P P 20000114
 US 2000-190471P P 20000317
 US 2000-193482P P 20000329
 US 2000-205231P P 20000515
 US 2000-213236P P 20000620
 US 2000-219865P P 20000720

=> s leptin(w)receptor(w) (antisense or interfering)
 L11 0 LEPTIN(W) RECEPTOR(W) (ANTISENSE OR INTERFERING)

=> s leptin(w)receptor and (antisense or interfering)
 L12 53 LEPTIN(W) RECEPTOR AND (ANTISENSE OR INTERFERING)

=> dup rem
 ENTER L# LIST OR (END):112
 PROCESSING COMPLETED FOR L12
 L13 31 DUP REM L12 (22 DUPLICATES REMOVED)

=> s 113 and py<2002
 L14 13 L13 AND PY<2002

=> dis ti so au 114 1-13

L14 ANSWER 1 OF 13 MEDLINE on STN
 TI Leptin inhibits steroid biosynthesis by human granulosa-lutein cells.
 SO Hormone and metabolic research. Hormon- und Stoffwechselforschung.
 Hormones et metabolisme, (2001 Jun) 33 (6) 323-8.
 Journal code: 0177722. ISSN: 0018-5043.
 AU Ghizzoni L; Barreca A; Mastorakos G; Furlini M; Vottero A; Ferrari B;
 Chrousos G P; Bernasconi S

L14 ANSWER 2 OF 13 MEDLINE on STN
 TI Distribution of galanin-like peptide in the rat brain.

SO Endocrinology, (2001 Apr) 142 (4) 1626-34.
Journal code: 0375040. ISSN: 0013-7227.

AU Takatsu Y; Matsumoto H; Ohtaki T; Kumano S; Kitada C; Onda H; Nishimura O;
Fujino M

L14 ANSWER 3 OF 13 MEDLINE on STN
TI Galanin-like peptide (GALP) is a target for regulation by leptin in the
hypothalamus of the rat.

SO Endocrinology, (2000 Jul) 141 (7) 2703-6.
Journal code: 0375040. ISSN: 0013-7227.

AU Jureus A; Cunningham M J; McClain M E; Clifton D K; Steiner R A

L14 ANSWER 4 OF 13 MEDLINE on STN
TI [Evaluating genetics and environment in development of obesity].
Bewertung von Genetik und Umwelt fur die Entstehung von Ubergewicht.

SO Acta medica Austriaca, (1998) 25 (4-5) 129-30. Ref: 6
Journal code: 7501997. ISSN: 0303-8173.

AU Lechleitner M; Hoppichler F

L14 ANSWER 5 OF 13 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Galanin-like peptide mRNA in the hypothalamus is regulated by leptin.

SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
No.-440.10. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.

AU Jureus, A. [Reprint author]; Cunningham, M. J.; McClain, M.; Clifton, D.
K.; Steiner, R. A.

L14 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
TI Use of cDNAs encoding cytoplasmic domain of mouse and human Ob (leptin)
receptors in diagnosis and treatment of body weight disorders

SO U.S., 49 pp., Cont.-in-part of U.S. Ser. No. 569,485, abandoned.
CODEN: USXXAM

IN Tartaglia, Louis Anthony; Tepper, Robert I.; Culpepper, Janice A.

L14 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
TI Use of cDNAs encoding mouse and human Ob (leptin) receptors in diagnosis
and treatment of body weight disorders

SO U.S., 75 pp., Cont.-in-part of U.S. Ser. No. 570,142, abandoned.
CODEN: USXXAM

IN Tartaglia, Louis A.; Tepper, Robert I.; Culpepper, Janice A.

L14 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
TI Methods and compositions for control of bone formation via modulation of
leptin activity

SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2

IN Karsenty, Gerard; Ducy, Patricia; Amling, Michael

L14 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
TI Human and murine isoforms of the Ob receptor and their use in methods of
identifying compounds that modulate body weight

SO U.S., 88 pp., Cont.-in-part of U.S. Ser. No. 583,153.
CODEN: USXXAM

IN Tartaglia, Louis A.; Tepper, Robert I.; Culpepper, Janice A.

L14 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
TI Cloning of cDNA for a human **leptin receptor** variant
and methods for detecting variants and regulating obesity

SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2

IN Snodgrass, H. Ralph; Cioffi, Joseph; Zupancic, Thomas J.; Shafer, Alan W.

L14 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

TI Cloning of cDNA for a human **leptin receptor** variant
and methods for detecting the variant and regulating obesity
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
IN Snodgrass, H. Ralph; Cioffi, Joseph; Zupancic, Thomas J.; Shafer, Alan W.

L14 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
TI Cloning of cDNA for db gene encoding the receptor for leptin and use of
the receptor
SO PCT Int. Appl., 171 pp.
CODEN: PIXXD2
IN Friedman, Jeffrey M.; Lee, Gwo-hwa; Proenca, Ricardo; Ioffe, Ella

L14 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
TI Human **leptin receptor** variant and its detection and
therapeutic use
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
IN Snodgrass, H. Ralph; Cioffi, Joseph; Zupancic, Thomas J.; Shafer, Alan W.

=> dis his

(FILE 'HOME' ENTERED AT 11:26:51 ON 01 SEP 2005)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 11:27:12 ON 01 SEP 2005

E COUTURIER/AU
L1 0 S E18 AND E30
L2 0 S E18,30
L3 131 S E18
L4 147 S E18 OR E30
L5 93 DUP REM L4 (54 DUPLICATES REMOVED)
L6 1 S L5 AND LEPTIN AND ANTISENSE
L7 45 S OB-RGRP
L8 114357 S ANTISENSE OR SIRNA
L9 4 S L7 AND L8
L10 4 DUP REM L9 (0 DUPLICATES REMOVED)
L11 0 S LEPTIN(W)RECEPTOR(W) (ANTISENSE OR INTERFERING)
L12 53 S LEPTIN(W)RECEPTOR AND (ANTISENSE OR INTERFERING)
L13 31 DUP REM L12 (22 DUPLICATES REMOVED)
L14 13 S L13 AND PY<2002

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	75.18	75.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

STN INTERNATIONAL LOGOFF AT 11:37:09 ON 01 SEP 2005